Skip to content

Efficacy and safety of a novel low-dose triple single-pill combination, compared with dual combinations for treatment of hypertension

By

In George Medicines’ Phase III trial among 1,385 patients in Australia, Czech Republic, New Zealand, Poland, Sri Lanka, UK and the US, standard- and half-dose forms of GMRx2 were tested against dual combinations of its component drugs. GMRx2 significantly reduced blood pressure and improved control rates vs dual therapy, with good tolerability and no increase …

Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria

By

Among Black African adults with uncontrolled hypertension, a low-dose triple-pill protocol achieved better blood pressure lowering and control with good tolerability compared with the standard-care protocol, according to the VERONICA (deliVERy of Optimal blood pressure coNtrol in afrICA) trial – the first trial to evaluate a low-dose triple combination pill as initial or early therapy …

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension

By

In George Medicines’ placebo-controlled Phase III trial of GMRx2, among patients in Australia, Nigeria, Sri Lanka, UK and the US, comparing half- and quarter-doses of GMRx2 against a placebo pill, GMRx2 significantly improved home- and clinic-measured blood pressure and control rates, in both half- and quarter-doses. Tolerability to GMRx2 was good, with no increase in withdrawal …

Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension

By

George Medicines’ Chief Medical Officer, Professor Anthony Rodgers, and steering committee members of the Company’s GMRx2 phase III trial programme examine the rationale for the single-pill, once-daily, triple combination of best-in-class medicines for the treatment of hypertension, including first-line therapy. Low-dose triple combinations have shown great promise to lead to a step change in hypertension …